Tyra Biosciences (NASDAQ:TYRA) Trading Down 2%

Tyra Biosciences, Inc. (NASDAQ:TYRA) was down 2% during trading on Wednesday . The company traded as low as $16.21 and last traded at $16.37. Approximately 2,632 shares changed hands during mid-day trading, a decline of 98% from the average daily volume of 145,034 shares. The stock had previously closed at $16.70.

Analyst Ratings Changes

A number of research analysts have commented on TYRA shares. Wedbush reaffirmed an “outperform” rating and issued a $28.00 target price on shares of Tyra Biosciences in a research report on Wednesday. Oppenheimer restated an “outperform” rating and set a $28.00 target price (up from $25.00) on shares of Tyra Biosciences in a research note on Monday, May 13th. Finally, HC Wainwright restated a “buy” rating and set a $23.00 target price on shares of Tyra Biosciences in a research note on Wednesday.

Tyra Biosciences Price Performance

The firm has a market cap of $873.21 million, a PE ratio of -10.04 and a beta of 1.01. The business has a 50-day moving average price of $17.62 and a two-hundred day moving average price of $16.57.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.11. Equities analysts expect that Tyra Biosciences, Inc. will post -1.71 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, COO Daniel Bensen sold 3,502 shares of the business’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $20.00, for a total transaction of $70,040.00. Following the transaction, the chief operating officer now directly owns 427,981 shares of the company’s stock, valued at approximately $8,559,620. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 15.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Tyra Biosciences

Several hedge funds and other institutional investors have recently modified their holdings of the company. Federated Hermes Inc. boosted its holdings in shares of Tyra Biosciences by 1,244.2% during the fourth quarter. Federated Hermes Inc. now owns 2,070 shares of the company’s stock valued at $29,000 after acquiring an additional 1,916 shares during the period. Exchange Traded Concepts LLC raised its holdings in Tyra Biosciences by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 9,531 shares of the company’s stock worth $132,000 after buying an additional 2,417 shares during the period. AJOVista LLC acquired a new stake in Tyra Biosciences during the 4th quarter worth about $59,000. Wellington Management Group LLP raised its holdings in Tyra Biosciences by 8.8% during the 4th quarter. Wellington Management Group LLP now owns 102,436 shares of the company’s stock worth $1,419,000 after buying an additional 8,324 shares during the period. Finally, Fishman Jay A Ltd. MI purchased a new position in Tyra Biosciences during the 1st quarter valued at about $246,000. Institutional investors and hedge funds own 84.14% of the company’s stock.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.